Intervention

A166

ClinicalTrials.gov intervention label

Clinical trials4
Recruiting1
Common conditions25
Lead sponsors shown2

Clinical trials

4 shown
A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerNCT07299825 · 2024-09-20
RECRUITING
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane TherapyNCT06968585 · 2023-07-18
ACTIVE_NOT_RECRUITING
A Study of A166 in Patients With Advanced Solid Malignant TumorsNCT05311397 · 2018-08-01
COMPLETED
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 GeneNCT03602079 · 2018-07-16
COMPLETED

Common conditions

HER2-positive Breast Cancer2Bile Duct Cancer1Bladder Cancer1Breast Cancer1Breast Neoplasm Malignant Primary1Cervical Cancer1Cholangiocarcinoma1Colo-rectal Cancer1Head and Neck Cancer1Head and Neck Carcinoma1Her 2 Positive Breast Cancer1HER-2 Gene Amplification1HER2 Gene Mutation1HER2 Positive Gastric Cancer1Larynx Cancer1Lip Cancer Stage I1Liver Cancer1Lung Cancer1Mouth Cancer1Mucinous Adenocarcinoma Gastric1Mucinous Breast Cancer Recurrent1Mucoepidermoid Carcinoma1Palate Cancer1Pancreatic Cancer1Primary Peritoneal Carcinoma1

Trial status mix

COMPLETED2
ACTIVE_NOT_RECRUITING1
RECRUITING1

Phase mix

PHASE12
PHASE22
PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.